Review: A review of the use of zonisamide in Parkinson’s disease

Abstract

Although zonisamide was previously only used to treat epilepsy, recently more applications have been forthcoming. Due to a good side effect profile, a lower frequency of interactions and a more comfortable posology, there are several studies regarding its uses in other pathologies such as migraine, neuropathic pain, essential tremor and various psychiatric diseases. A multicentered, randomized, double-blind, placebo-controlled study conducted in Japan suggested that zonisamide, as an add-on treatment, has efficacy in treating motor symptoms in patients with Parkinson’s disease. In addition, other studies support the utility of zonisamide in other symptoms of this disease. The therapeutic doses of zonisamide for the treatment of Parkinson’s disease are considerably lower than those for the treatment of epilepsy. This antiepileptic drug has been used in Japan for more than 15 years and so it is expected that it will be safe and well tolerated in patients with Parkinson’s disease. However, the pharmacological mechanisms of the antiparkinsonian actions of zonisamide remain unclear and more basic investigation is warranted. The aim of this paper is to review the structure, mechanisms of action, pharmacokinetics and antiparkinsonian action of zonisamide.

Keywords

antiepileptic neuromodulator Parkinson’s disease zonisamide

References

Arzimanoglou, A. and Rahbani, A. ( 2006) Zonisamide for the treatment of epilepsy. Expert Rev Neurother 6: 1283-1292.

Bazil, C.W. ( 2004) Anticonvulsant drug or neuromodulator? The growing case for anticonvulsant uses beyond epilepsy. Curr Neurol Neurosci Rep 4: 305-307.

Bermejo, P.E. ( 2008) Topiramate in managing impulse control disorders in Parkinson’s disease. Parkinsonism Relat Disord 14: 448-449.

Bermejo, P.E. ( 2007) Zonisamide in patients with essential tremor and Parkinson’s disease. Mov Disord 22: 2137-2138.

Bermejo, P.E. and Dorado, R. Zonisamide for migraine prophylaxis in refractory patients to topiramate. Clin Neuropharmacol, in press.

Bermejo, P.E. , Gomez-Argüelles, J.M. and Sepúlveda, J.M. ( 2008) Role of antiepileptic drugs in Parkinson’s disease . Med Clin (Barc) 131: 466-471.

Bermejo, P.E. , Ruiz-Huete, C. , Dorado, R. and Anciones, B. ( 2008) Zonisamide in refractory essential tremor. Rev Neurol 46: 139-142.

Bermejo, P.E. and Velasco, R. ( 2008) Zonisamide in managing impulse control disorders in Parkinson’s disease. J Neurol 255(Suppl 2): 167 [Abstract].

Bermejo, P.E. , Zabala, J.A. and Saez, R. ( 2007) Restless legs syndrome induced by zonisamide. Mov Disord 22: 1517-1518.

10.

Biton, V. ( 2007) Clinical pharmacology and mechanism of action of zonisamide . Clin Neuropharmacol 30: 230-240.

11.

Carod-Artal, F.J. , Ziomkowski, S. , Mourao Mesquita, H. and Martínez-Martín, P. (2008) Anxiety and depression: Main determinants of health-related quality of life in Brazilian patients with Parkinson’s disease. Parkinsonism Relat Disord 14: 102-108.

12.

Chen, J.T. , Garcia, P.A. and Alldredge, B.K. ( 2003) Zonisamide-induced restless legs syndrome. Neurology 60: 147.

13.

Friedman, J.H. , Brown, R.G. , Comella, C. , Garber, C.E. , Krupp, L.B. , Lou, J.S. et al. (2007) Fatigue in Parkinson’s disease: a review . Mov Disord 22: 297-308.

14.

Gluck, M.R. , Santana, L.A. , Granson, H. and Yahr, M.D. ( 2004) Novel dopamine releasing response of an anticonvulsant agent with possible anti-Parkinson’s activity. J Neural Transm 111: 713-724.

15.

Gómez-Esteban, J.C. , Zarranz, J.J. , Tijero, B. , Velasco, F. , Barcena, J. , Rouco, I. et al. (2007) Restless legs syndrome in Parkinson’s disease. Mov Disord 22: 1912-1916.

16.

Guay, D.R. ( 2003) Oxcarbazepine, topiramate, zonisamide, and levetiracetam: potential use in neuropathic pain. Am J Geriatr Pharmacother 1: 18-37.

17.

Huang, C.W. , Ueno, S. , Okada, M. and Kaneko, S. ( 2005) Zonisamide at clinically relevant concentrations inhibits field EPSP but not presynaptic fiber volley in rat frontal cortex. Epilepsy Res 67: 51-60.

18.

Jankovic, J. ( 2006) An update on the treatment of Parkinson’s disease . Mt Sinai J Med 73: 682-689.

19.

Kajimoto, Y. , Nakanishi, I. and Kondo Wakayama, T. ( 2008) One year follow-up study of the zonisamide (ZNS) efficacy on parkinsonism. Mov Disord 23(Suppl 1): 214 [Abstract].

20.

Kashihara, K. ( 2006) Weight loss in Parkinson’s disease. J Neurol 253: 38-41.

21.

Kinrys, G. , Vasconcelos e Sa, D. and Nery, F. ( 2007) Adjunctive zonisamide for treatment refractory anxiety . Int J Clin Pract 61: 1050-1053.

22.

Konitsiotis, S. , Blanchet, P.J. , Verhagen, L. , Lamers, E. and Chase, T.N. ( 2000) AMPA receptor blockade improves levodopa-induced dyskinesia in MPTP monkeys. Neurology 54: 1589-1595.

23.

Kubo, M. , Nishikawa, N. , Yabe, H. , Nagai, M. , Moritoyo, H. , Moritoyo, T. et al. (2008) Zonisamide increased metabolism of dopamine neurons in MPTP-treated C57BL/6 and common marmosets. Mov Disord 23(Suppl 1): 311 [Abstract].

24.

Michael, C.T. and Starr, J.L. ( 2007) Psychosis following initiation of zonisamide. Am J Psychiatry 164: 682.

25.

Miwa, H. ( 2007) Zonisamide for the treatment of Parkinson’s disease . Expert Rev Neurother 7: 1077-1083.

26.

Morita, S. , Miwa, H. and Kondo, T. ( 2005) Effect of zonisamide on essential tremor: a pilot crossover study in comparison with arotinolol. Parkinsonism Relat Disord 11: 101-103.

27.

Murata, M. , Hasegawa, K. and Kanazawa, I. ( 2007) Zonisamide improves motor function in Parkinson disease: a randomized, double-blind study. Neurology 68: 45-50.

28.

Murata, M. , Horiuchi, E. and Kanazawa, I. ( 2001) Zonisamide has beneficial effects on Parkinson’s disease patients. Neurosci Res 41: 397-399.

29.

Nakanishi, I. , Kohmoto, J. , Miwa, H. and Kondo, T. ( 2003) Effect of zonisamide on resting tremor resistant to antiparkinsonian medication. No To Shinkei 55: 685-689.

30.

Ondo, W.G. ( 2007) Zonisamide for essential tremor. Clin Neuropharmacol 30: 345-349.

31.

Wichmann, T. and DeLong, M.R. ( 2006) Basal ganglia discharge abnormalities in Parkinson’s disease. J Neural Transm 70: 21-25.

32.

Willmore, L.J. ( 2005) Antiepileptic drugs and neuro-protection: current status and future roles. Epilepsy Behav 7(Suppl. 3): 25-28.

33.

Zesiewicz, T.A. , Ward, C.L. , Hauser, R.A. , Sanchez-Ramos, J. , Staffetti, J.F. and Sullivan, K.L. ( 2007) A double-blind placebo-controlled trial of zonisamide (zonegran) in the treatment of essential tremor. Mov Disord 22: 279-282.